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 Angiotensin converting enzyme (ACE) inhibitors remain the foundation of treatment for heart failure 
with reduced ejection fraction (HFREF) [1]. Angiotensin receptor blockers (ARB) are recommended 
as an alternative if the patient cannot tolerate an ACE inhibitor as a result of the CHARM-Alternative 
trial [2]. In many Asian countries ARBs are given as a first line drug, rather than ACE inhibitors, as 
many Asian patients fail to tolerate ACE inhibitors due to cough[3]. The reason for this racial 
disparity in the incidence of ACE inhibitor induced cough is not fully understood. However, many 
clinicians prescribe an ARB, before an ACE inhibitor, to Asian patients with HFREF. But does the 
benefit of an ARB persist in the real world, and, in a population that seem to react differently to ACE 
inhibitors? Answering this question is difficult. The best option would be to conduct a well-designed, 
and adequately powered, randomized clinical trial. However, clinical trials are costly and require a 
massive amount of effort on the part of investigators and patients alike. Can alternative data sources 
help answer specific questions (such as whether ARBs are effective in Asians) when there is already a 
solid foundation of evidence for their use from a large well conducted randomised trial?  One option 
is to examine the Asian subgroup of a randomised trial. However, these are fraught with difficulty [4] 
and the subgroup may not exist or be large enough to assuage any apprehension. For these reasons 
many have turned to registries.  
  
There has been a sharp increase in the use of registries to examine the association between 
treatments and outcomes. The difficulties surrounding such analyses have been widely discussed [5]. 
Randomisation overcomes the problems of registry based data but if used responsibly, registries can 
provide information on the use of a drug in real world populations outside the selected populations 
of clinical trials. Registries can answer specific questions that would never merit the cost and effort 
of a large randomised trial. More importantly they can reveal other avenues for research.  
 
Choi and colleagues [6] used a registry to examine the use of ARBs in Asian patients with HFREF. 
Using a Korean registry of patients with decompensated heart failure they examined the association 
between ARB use and all-cause death and compared those who received an ARB to those who 
received an ACE inhibitor, and those who received neither. There were similarities to the patients 
enrolled in CHARM-Alternative (the mean age was 67 years and around two thirds were men) and 
differences (they were acutely decompensated, the prevalence of comorbidities was higher). The 
hazard of death was similar in the ACE inhibitor compared to the ARB group 0.91 (95%CI 0.76-
1.09,p=0.32) after propensity adjustment. Compared to the group who did not receive any blockers 
of the renin angiotensin aldosterone system the hazard of death in the ARB group was 0.69 (95%CI 
0.56-0.83,p<0.001). However, candesartan did not reduce all-cause mortality in CHARM-Alternative 
(HR=0.87,95%CI 0.74–1.03,p=0.11) yet Choi et al [6] report a 31% relative risk reduction. There is 
always the statistical possibility that this is true but it is more likely that this is due to unmeasured 
confounding [5]. Although propensity score weighting tries to overcome confounding by matching 
similar patients, it is not perfect and in this study matching was suboptimal. This highlights the need 
to exercise caution when interpreting the result of such analyses.  
 
If registry data cannot ever establish the efficacy of ARBs, what can they do? Registries can provide 
information on treatment use and discontinuation rates. In a well-run clinical trial discontinuation 
rates are often low, in contrast to the multi-morbid patient with polypharmacy that heart failure 
specialists see in daily clinical practice. Discontinuation rates were high, 21% of those receiving an 
ARB and 34% of those receiving an ACE inhibitor discontinued it by 1 year. These numbers should 
worry heart failure specialists and remind us that our job does not stop after prescribing a drug, we 
must try and help our patients remain on the drug.  
 
Registry based analyses can provide data on the treatment of conditions when randomised trials are 
not possible, such as in rare diseases or rare outcomes, and can allow exploration of groups not 
studied in randomised trials. Patients with heart failure with mid-range ejection fraction (HFMREF), 
an ejection fraction in the range of 40-49% [1,7], are such a group. Choi et al [6] found 839(16%) 
patients with HFMREF and 1309(25%) with heart failure with preserved ejection fraction (HFPEF), 
EF≥50%.  They reported that the survival of patients with HFMREF receiving an ACE inhibitor or ARB 
was similar, and, better than those not receiving either, in HFPEF there was no difference.  Could this 
simply be another statistical anomaly? A recent analysis of the beta-blocker trials reported that 
patients HFMREF may benefit from beta-blockers like those with HFREF [8].  Could renin angiotensin 
aldosterone system inhibition be similarly beneficial in HFMREF? In the TOPCAT trial there was a 
trend towards benefit in those with an EF of <50% compared to those with an EF >60% [9]. Another 
analysis of the CHARM trials also suggested that those with HFMREF demonstrated a similar 
response to candesartan as those with HFREF [10]. The data from Choi et al [6] therefore add to this 
growing body of evidence that patients with HFMREF may respond to drugs in a similar way to those 
with HFREF. 
 
Registry based analyses are becoming more prevalent and their use looks set to continue to rise. 
With careful analysis, of the right question, with appropriate caution in the interpretation of the 
results and acknowledgment of the limitations, registry based analyses can help confirm the results 
of randomised controlled trials and answer specific questions about the real world use and tolerance 
of drugs in clinical practice. Registry based analyses are strongest when supported by a solid 
foundation of randomised trial evidence and interpretation should always be done with caution and 
with full consideration of the randomised evidence where it exists. If the reader keeps this in mind, 
new, and clinically important, insights can be gained.  
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